Targeting autophagy inhibits melanoma growth by enhancing NK cell infiltration in a CCL5-dependent manner


*Laboratory of Experimental Cancer Research, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg City, Luxembourg; 1Life Sciences Research Unit, University of Luxembourg, L-4367 Belvaux, Luxembourg; 2National Cytometry Platform, Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg; 3INSERM UMR 1186, Gustave Roussy Cancer Center, 94805-Villejuif, France; 4INSERM UMR 981, Gustave Roussy Cancer Center, 94805-Villejuif, France; 2Laboratoire National de Santé, L-3555 Dudelange, Luxembourg; and 6Department of Hemato-oncology, Centre Hospitalier du Luxembourg, 1210 Luxembourg City, Luxembourg

Edited by Charles G. Drake, Johns Hopkins Medical Institutions, Baltimore, MD, and accepted by Editorial Board Member Philippa Marrack September 20, 2017 (received for review March 8, 2017)

While blocking tumor growth by targeting autophagy is well established, its role on the infiltration of natural killer (NK) cells into tumors remains unknown. Here, we investigate the impact of targeting autophagy gene Beclin1 (BECN1) on the infiltration of NK cells into melanomas. We show that, in addition to inhibiting tumor growth, targeting BECN1 increased the infiltration of functional NK cells into melanoma tumors. We provide evidence that driving NK cells to the tumor bed relied on the ability of autophagy-defective tumors to transcriptionally upregulate the chemokine gene CCL5. Such infiltration and tumor regression were abrogated by silencing CCL5 in BECN1-defective tumors. Mechanistically, we show that the up-regulated expression of CCL5 occurred through the activation of its transcription factor c-Jun by a mechanism involving the impairment of phosphatase PP2A catalytic activity and the subsequent activation of JNK. Similar to BECN1, targeting other autophagy genes, such as ATG5, p62/SQSTM1, or inhibiting autophagy pharmacologically by chloroquine, also induced the expression of CCL5 in melanoma cells. Clinically, a positive correlation between CCL5 and NK cell marker NKP46 expression was found in melanoma patients, and a high expression level of CCL5 was correlated with a significant improvement of melanoma patients’ survival. We believe that this study highlights the impact of targeting autophagy on the tumor infiltration by NK cells and its benefit as a novel therapeutic approach to improve NK-based immunotherapy.

significance

The failure in achieving a durable clinical immune response against cancer cells depends on the ability of cancer cells to establish a microenvironment that prevent cytotoxic immune cells to infiltrate tumors and kill cancer cells. Therefore, the key approach to achieving successful antitumor immune response is to harness strategies allowing the reorientation of immune cells to the tumor. Herein we reveal that inhibiting autophagy induces a massive infiltration of natural killer immune cells into the tumor bed, and a subsequent dramatic decrease in the tumor volume of melanomas. These results highlight the role of targeting autophagy in breaking the immunosuppressive tumor microenvironment barrier, thus allowing the infiltration of natural killer cells into the tumor to kill cancer cells.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission. C.G.D. is a guest editor invited by the Editorial Board.

This is an open access article distributed under the PNAS license.

1To whom correspondence should be addressed. Email: bassam.janji@lih.lu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1703921114/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1703921114

PNAS PLUS

PNAS | Published online October 16, 2017 | E9271–E9279

autophagy | melanoma | natural killer | CCL5 | immunotherapy

Natural killer (NK) cells are known to be a critical part of the immune system involved in tumor control. In human and animal models, NK cell deficiency leads to increased incidence of different types of tumors (1). While the role of NK cells in tumor immune surveillance is well established and experimentally supported (2), the use of NK cells is far from being successfully and fully used in the clinic, although efforts are now being undertaken to exploit their antitumor properties (3). This might be in part related to the lack of crucial knowledge about NK cell-homing capacities (4, 5) and their poor infiltration into solid tumors (6). Indeed, the long-lasting observations showing that NK cells are infrequently detected in tumor biopsies suggest that intratumoral NK cells can be associated with increased survival of cancer patients (7). Therefore, strategies aiming at increasing the infiltration of NK cells into tumors would be of great interest to improve NK-based tumor immunotherapies (8). Consequently, a deeper understanding of the mechanisms regulating NK cell infiltration will allow us to take full advantage of the tremendous antitumor capacities of NK cells and rapidly bring them to the clinical use.

In this regard, it should be emphasized that the infiltration of functional cytotoxic immune cells, including NK and cytotoxic T lymphocytes (CTLs), will likely become a major factor in achieving successful immunotherapies, notably those based on the use of immune checkpoint inhibitors. Accumulating new evidence highlights that, similar to CTLs, activated NK cells can express, under some circumstances, the immune checkpoint programmed cell death protein 1- (PD-1) (9-11) and CTL-associated antigen 4 (CTLA4) (12). Thus, it stands to reason that improving the infiltration of cytotoxic immune cells, including NKs, into the tumor bed could enhance the therapeutic benefit of NK cell-based immunotherapy and provide novel therapeutic targets that could complement the expanding armamentarium of cancer immunotherapies.

Chemokines are chemotactic cytokines playing a major role in the infiltration of immune cells into the tumor bed, and are therefore supposed to play a tumor-suppressive role (13). However, depending on the balance between several tumor-promoting and tumor-inhibiting factors, some cytokines may play a dual role in tumor promotion or tumor suppression. For example, several cytokines expressed by melanomas are involved in tumor growth.
and progression, including CXCL1, CXCL2, CXCL3, CXCL8, CCL2, and CCL5 (14). In contrast, it has been shown that chemotherapy can also induce the expression of cytokines, including CCL5, involved in the trafficking of T cells into the tumor bed (15). Therefore, a positive correlation between the expression of some cytokines and the clinical outcome has been proposed (16). It is now well defined that the dual role played by some cytokines as tumor-promoting or tumor-suppressing depends on the balance between tumor-promoting and tumor-inhibiting factors. Therefore, understanding the complex role of chemokines in tumor biology and the context by which they play such a dual role will contribute to the improvement of the efficacy of cancer immunotherapeutic strategies and the induction of long-lasting host antitumor immunity.

Using syngeneic melanoma and breast mouse models, we have previously reported that targeting the autophagy gene Beclin1 (BECN1) significantly inhibited tumor growth by improving NK-mediated antitumor immune response (17). Briefly, autophagy is a lysosomal degradation pathway executed at the basal level that allows cells to self-digest their own components and rid themselves of damaged organelles and misfolded proteins in well-defined structures, named autophagosomes. Such a degradation process provides nutrients to maintain cellular functions under environmental stresses, thus allowing survival of cancer cells under stress conditions (18, 19). Autophagy involves a BECN1/class III phosphoinositide-3-kinase (PI3K) complex to initiate the formation of an isolation membrane, called the phagophore (20). ATG5, another autophagy-related protein, plays a role in the elongation of the phagophore and in its subsequent maturation into the complete autophagosome (21). Consistent with the degradation property of autophagy, we have demonstrated that targeting BECN1 prevented the degradation of NK-derived Granzyme B (GzmB) in hypoxic melanoma cells, and therefore restored their susceptibility to NK cell-mediated killing (17). A growing body of evidence suggests that autophagy could operate in tumor cells as an immunosuppressive and cell-resistance mechanism, because autophagy blockade not only sensitizes tumor to chemotherapy (22) but also improves the antitumor immune response (23, 24).

In this study, we investigated the impact of targeting autophagy on the infiltration of NK cells into the tumor bed. We show that targeting BECN1 in melanoma tumor induced a massive infiltration of functional NK cells into the tumor by a mechanism involving the secretion of high levels of CCL5, since the infiltration was no longer observed after silencing CCL5. In autophagy-defective tumor cells, we provide evidence that the induction of CCL5 is transcriptionally related to the increase in the phosphorylation of c-Jun at Ser-63 and -73. We also provide clinical evidence supporting our data by showing a positive correlation between the expression of CCL5 and the NK cell marker NKP46 in melanoma patients. In addition, high expression of CCL5 was correlated with an overall improved survival of melanoma patients.

Results
Targeting Autophagy Related Gene BECN1 Improves the Recruitment of Functional NK Cells into the Tumor Bed. We have previously reported that targeting BECN1 significantly reduces the growth of B16-F10 mouse tumors. This effect is primarily related to the improvement of NK-mediated tumor cell killing, as such reduction was no longer observed in NK cell-depleted mice (17). Although NK cells seem to play a major role in the control of B16-F10 tumor growth, it should be emphasized that the reduced BECN1-defective (BECN1−) B16-F10 tumor volume was also rescued, but to a lesser extent, by the depletion of CD8 T cells. In this study, we investigated whether targeting BECN1 inhibits the tumor growth by improving the infiltration of NK cells into the tumor bed. Immunohistochemistry staining of tumor sections revealed a massive infiltration of NK cells into BECN1− compared with control (Ctrl) tumors (Fig. L4).

Since NK cell-infiltrating tumors could be functionally impaired/exhausted (25), we then assessed the functional properties of the NK cells that infiltrated BECN1− tumors. Flow cytometry analysis, performed based on the gating strategy described in Fig. S1, on Ctrl and BECN1− B16-F10 tumors confirmed our results obtained by immunohistochemistry result and revealed an almost twofold increase in the number of NK cell-infiltrating BECN1− tumors compared with Ctrl (Fig. 1 B and C). Furthermore, our data show that infiltrated NK cells were CD69+ and GzmB+, indicating that they were fully functional in the BECN1− tumor bed (Fig. 1 B and C). Interestingly, when reported to the total number of NK cells, no difference in the activation status of NK cells infiltrating both Ctrl and BECN1− tumors was found (Fig. 1D). This result shows that targeting BECN1 increases the number of infiltrated NK cells without affecting their activation properties. Together, our data highlight that targeting BECN1 presumably inhibits the growth of B16-F10 tumors at least in part by improving the homing of functional NK cells into the tumor bed.

![Fig. 1. BECN1− B16-F10 tumors contain higher numbers of active NK cells compared with Ctrl tumors. (A) Immunohistochemical staining of NK cells performed on control (Ctrl) or BECN1− B16-F10 tumor sections using anti-Asialo-GM1. (Scale bar, 200 μm.) (B) Tumor-infiltrating NK cells were stained with NK1.1, CD69, and GzmB-specific antibodies. Total NK cells (CD45+NK1.1+) were gated and the percentage of active NK cells (NK1.1+CD69+ and NK1.1+GzmB+) was determined by multicolor flow cytometry. Images represent flow cytometric plots of CD45+NK1.1+, NK1.1+CD69+, and NK1.1+GzmB+ cells infiltrating Ctrl and BECN1− B16-F10 tumors. (C) Quantification of total NK1.1+ and active (NK1.1+CD69+ and NK1.1+GzmB+) NK cells infiltrating Ctrl and BECN1− B16-F10 tumors, reported as a percentage (%). (D) Quantification of CD69+/NK1.1− (Left) and GzmB+/NK1.1− (Right) cells infiltrating control Ctrl and BECN1− B16-F10 tumors, reported as a percentage (%). Results are the average ± SEM of three mice from each group. *P < 0.05; **P < 0.01; ns, not significant (two-tailed Student’s t test).]
Targeting Autophagy Induces the Expression of CCL5, Which Is Involved in the Migration of NK Cells. It is well established that tumors displaying high number of cytotoxic immune cells secrete high amounts of attracting chemokines (26, 27). Consequently, we evaluated whether the improvement of the infiltration of NK cells into BECN1-B16-F10 tumors is related to the regulation of some chemokines involved in the migration of NK cells. A cytokine profiling assay, performed using the conditioned medium of tumor cells, revealed that targeting BECN1 increased the secretion of several chemokines, including CCL5, CXCL10, and TIMP1 (Fig. 2A, Left). The quantification of the results obtained by cytokine arrays revealed that CCL5 was the predominant up-regulated cytokine in BECN1− tumor cells compared with CXCL10 or TIMP1 (Fig. 2A, Right). Based on these data, we focused our interest on CCL5 and quantified its level in the conditioned media of Ctrl and BECN1− B16-F10 tumor cells by ELISA. Fig. 2B shows that BECN1− cells secreted 4.5-fold more CCL5 compared with Ctrl cells (525 and 112 pg/mL for BECN1− and Ctrl, respectively).

The impact of targeting BECN1 on the expression of CCL5 was further assessed in human melanoma cell lines displaying low levels of CCL5. Indeed, according the expression value (log2) of CCL5 in 62 human melanoma cell lines reported by the Cancer Cell Line Encyclopedia (https://software.broadinstitute.org/morpheus), we selected three human melanoma cell lines—A375, IPC298, and MelJuso—displaying a relatively low expression level of CCL5 mRNA (Fig. S2). Fig. 2C shows that, similarly to B16-F10 cells, targeting BECN1 in A375, IPC298, and MelJuso human melanoma cell lines induced a significant increase in the secretion of CCL5, indicating that the up-regulation of CCL5 resulting from targeting BECN1 is not restricted to B16-F10 but can also be observed in other human melanoma cell lines.

To further determine the involvement of CCL5 in the migration of NK cells, we tracked the migration of human NK cells toward a CCL5 gradient, using ibidi slides and a cell IQ platform. Fig. 2D shows that, in the absence of CCL5, NK cells migrate randomly (50% of cells to the upper and 50% to the lower compartments) in short-distance migration trajectories. Interestingly, the presence of a CCL5 gradient in the upper compartment induced directional long-distance migration of 80% of the NK cells toward that compartment. These results strongly suggest that CCL5 is a key determinant for the migration of NK cells.

A growing body of evidence has revealed that, in addition to its role in autophagy, BECN1 has several nonautophagic functions (28). We therefore investigated whether targeting other autophagy genes could also induce CCL5. We first determined whether CCL5 is regulated at mRNA level. Our results (Fig. 2E) show that, in BECN1− tumor cells, CCL5 is up-regulated at the transcription level as a significant increase in the mRNA of CCL5 was observed in BECN1− B16-F10 cells. Next, to determine to what extent the autophagy process is involved in the regulation of CCL5, we evaluated the impact of targeting other autophagy genes on the expression of CCL5. We show that, similarly to BECN1, targeting ATG5 or p62/SQSTM1 or treating cells with chloroquine, an autophagy inhibitor (Fig. 2F), resulted in a significant increase in the expression of CCL5 mRNA in B16-F10 melanoma cells. Taken together, these data provide clear evidence that—not only BECN1 but also the autophagy process—are involved in the regulation of CCL5.

Targeting BECN1 Induces the Expression of CCL5 Transcription Factor c-Jun. To gain more insight into the molecular mechanisms involved in the up-regulation of CCL5 mRNA in BECN1− B16-F10 cells, we focused our interest on the major transcription factor involved in the regulation of the CCL5 transcript. Indeed, the promoter region of mouse and human CCL5 contains several binding sites for well-defined transcription factors (29), including AP-1. We first assessed whether c-Jun binds to the CCL5 promoter in B16-F10 cells. We performed in silico identification of consensus (5′-TGA[C/G]TCA-3′) (30) and nonconsensus (5′-TGACTgA-3′ or 5′-TGACTCtC-3′) (31) motifs for the Jun/Fos
AP-1 binding site on the mouse CCL5 promoter. The promoter containing fragment has been defined using the Eukaryotic Promoter Database (Swiss Institute of Bioinformatics) from −8,000 to +100 bp relative to the transcription start site (TSS) of the mouse CCL5 gene (RefSeq NM_013653.3). Fuzznuc EMBOSS searches for patterns in nucleotide sequences software identified two consensus and two nonconsensus AP-1 binding sites, highlighted in red and green, respectively, on the sequence (shown in Fig. S3A). The positions of the consensus motifs were −7,668 and −5,489 and those of the nonconsensus motifs were −7,636 and −5,129 (Fig. S3B). ChIP was performed on CCL5-overexpressing BECN1−/− B16-F10 cells using anti-c-Jun ChIP grade antibody. Our results, depicted in Fig. S3C, show that c-Jun strongly binds to the nonconsensus 5′-TGACTA-3′ motif containing region C of the CCL5 promoter, indicating that CCL5 is a direct c-Jun target gene in BECN1−/− B16-F10 cells.

We next investigated the expression and the activation of c-Jun, the AP-1 founding member (32). It is known that c-Jun is trans-activated by phosphorylation at the N terminal Ser-63 and Ser-73 residues (33, 34). Our results showed that the total and the phosphorylated level of c-Jun at both Ser-63 and Ser-73 residues were higher in BECN1−/− compared with control B16-F10 cells (Fig. 3A, Left). An increase in the phosphorylation of c-Jun was also observed in BECN1−/− tumor extracts (Fig. 3A, Right).

C-Jun phosphorylation is mediated by the upstream kinase JNK, which in turn is activated by phosphorylated by MKK4 kinase (35). While no difference was observed in the total expression and the phosphorylation levels of MKK4, a significant increase in the phosphorylation of JNK at Thr-183 and Tyr-185 was detected in BECN1−/− compared with Ctrl cells (Fig. 3B, Left), suggesting that the increased phosphorylation level of c-Jun in BECN1−/− cells is most likely related to an increased JNK activity. This assumption was further supported by our data showing that pharmacological (Fig. 3C, Upper) and genetic (Fig. 3D, Upper) inhibition of JNK completely suppressed, as expected, the phosphorylation of c-Jun at Ser-63 and Ser-73 residues and, more interestingly, led to a significant down-regulation of CCL5 mRNA in BECN1−/− tumor cells (Fig. 3 C and D, Lower).

It has long been postulated that the regulation of protein phosphorylation is partially balanced by the activity of kinases and phosphatases. The serine/threonine phosphatase, PP2A, has been described to be involved in the regulation of JNK phosphorylation and subsequently in that of its downstream protein c-Jun (36). In accordance with this, we assessed PP2A activity in Ctrl and BECN1−/− B16-F10 cells to determine whether the increased levels of phosphorylated JNK and phosphorylated c-Jun are related to a defect in PP2A activity. The results (Fig. 3E) revealed that PP2A activity was significantly lower in BECN1−/− compared with Ctrl B16-F10 cells, suggesting that the increased levels of phosphorylated JNK and phosphorylated c-Jun resulted from a decrease in the phosphate activity of PP2A. This was further supported by our data showing that targeting PP2A subunit A genetically by siRNA in control cells increased the phosphorylation of both JNK and c-Jun (Fig. 3F, Left), and subsequently increased the expression of CCL5 (Fig. 3F, Right). Similarly, treatment of control cells with PP2A inhibitor okadaic acid inhibited its catalytic activity by increasing the phosphorylation at Tyr-307 (Fig. 3G, Upper). Such inhibition enhanced the phosphorylation of c-Jun at Ser-63 and increased the expression of CCL5 (Fig. 3G, Lower). Overall, these results provide a mechanistic clue on how targeting autophagy increases the expression of CCL5 by enhancing the phosphorylation of c-Jun.

Targeting CCL5 in BECN1−/− Tumors Significantly Reduces the Infiltration of NK Cells into the Tumor Bed and Prevents Tumor Regression. We next investigated the impact of silencing CCL5 on the tumor growth and on the infiltration of NK cells in BECN1−/− B16-F10 tumors. We generated B16-F10 cells defective for both
and CCL5 (BECN1+/CCL5−) and characterized them in terms of BECN1 expression and CCL5 secretion. Our results, shown in Fig. 4A, demonstrate a significant inhibition of the secretion of CCL5 in BECN1+/CCL5− cells. Fig. 4B clearly shows that the reduction of tumor growth, seen in BECN1+ tumors (Fig. 4B, red curve) compared with controls (Fig. 4B, black curve), was no longer observed when CCL5 was silenced (Fig. 4B, gray curve). Interestingly, immunohistochemistry staining demonstrated that targeting CCL5 in BECN1+ tumors dramatically prevented the infiltration of NK cells into the tumor bed (Fig. 4C). The quantification of the percentage of NK cells infiltrating the tumors is shown in Fig. 4D. These data provide additional support that the recruitment of NK cells into BECN1+ B16-F10 tumors is driven by CCL5. Because the JNK/c-Jun pathway has been identified in vitro as the major transcription factor involved in the up-regulation of CCL5 in BECN1+ tumor cells, we noticed that genetic targeting of JNK/c-Jun pathway (Fig. 4E) resulted in a dramatic decrease in CCL5 expression (Fig. 4F) and an increase in BECN1+ tumor volume (Fig. 4G) and weight (Fig. 4H). Interestingly, there was a significant decrease in both the expression of tumoral CCL5 (Fig. 4F) and the infiltration of NK cells into the tumor bed (Fig. 4F and Fig. S4). Overall, our data provide evidence that JNK/c-Jun/CCL5 pathway regulates the recruitment of NK cells into BECN1+ tumors.

The Expression of CCL5 Positively Correlates with Expression of the NK Cell Marker NKP46 and Predicts Improvement of Melanoma Patients’ Survival. We next investigated whether a positive correlation could be found between the expression of CCL5 and the infiltration of NK cells in melanoma patients. Sections of melanoma tumor biopsies were first stained with CCL5 and assigned, according to the expression level of CCL5, as low, moderate, high, and very-high CCL5 staining. These tumors were further stained with the NK cell marker NKP46. Our results reveal a striking positive correlation between the expression levels of CCL5 and NKP46 (Fig. 5A). Our data were further confirmed by quantitative real-time PCR performed using mRNA isolated from a panel of 22 melanoma biopsies (Fig. 5B). To extend our study to an even larger cohort of melanoma patients, we used data from 471 skin cutaneous melanomas described in the TCGA database. As expected, a strong positive correlation was also observed between the expression of CCL5 and the expression of the NKp46 encoding gene NCR1 (Fig. 5C). Taken together, these results highly suggest that melanoma tumors expressing high levels of CCL5 are strongly infiltrated by NK cells.

We next assessed the impact of CCL5 level on the survival of 458 melanoma patients using the recently described OncoLnc resource (www.oncolnc.org). This resource links RNAseq data of particular genes with patients’ survival using clinical data from The Cancer Genome Atlas (TCGA) (37). Based on RNAseq data, the median log expression level of CCL5 in melanoma patients was 588.44 (reported as a “log”). According to the expression level of CCL5, the 458 melanoma samples were assigned into low and high CCL5-expressing groups, each of them containing 229 samples. The expression of CCL5 in the low and high groups ranged from 7.92 to 588 and from 588 to 32,675, respectively. The Kaplan–Meier survival plot reported in Fig. 5D depicts that melanoma patients with an elevated expression level of CCL5 had a significant longer survival. Taken together, these data strongly suggest that the improvement of the survival of melanoma patients displaying a high level of CCL5 is most likely due to an increase in the infiltration of NK cells into the tumors.

Discussion

The role of NK cells in the improvement of immune responses to cancer has been extensively investigated during the past few decades, and several NK cell-based immunotherapies have been proposed and are used in the clinic (38).
CCL5, also known as RANTES, is a small protein that belongs to a large family of cytokines and displays chemotaxis activity, as it is involved in inducing the migration of several leukocytes into inflammation sites (39). CCL5 is secreted by a wide variety of cells, including T cells (40), NKs (27), and some tumor cells (41). CCL5 interacts with different receptors including C-C chemokine receptor types 1, 3, and 5 (CCR1, CCR3, and CCR5) (42). Controversial data exist about the role of CCL5 in the tumor microenvironment. Although the causal mechanisms underlying the decrease in PP2A activity in ATG5-defective cells and after chloroquine treatment, we strongly believe that targeting the autophagy mechanism as a whole, rather than specifically targeting BECN1, results in the improvement of the NK-mediated antitumor immune responses by inducing NK cell-homing into tumors.

It has been previously reported that CCL5 can increase the cytotoxicity of CD56+ human NK cells (44). Other studies also showed that CCL5 promotes the release of cytotoxic granules by human NK cells (45–47). We therefore asked whether an elevated level of CCL5 could enhance the cytolytic activity of NK cell-infiltrating tumors. We strongly believe that CCL5 released by BECN1− tumors has no impact on the activation status of NK cells as, when reported to the total number of NK cells, no differences in the expression of NK cell-activation markers CD69 and GzmB were observed in NK cell-infiltrating control or BECN1− tumors.

The Spearman test showed a significant and positive correlation between the expression of CCL5 and NKp46 encoding NCR1 gene. The Spearman test showed a significant and positive correlation between the expression of CCL5 and NCR1 (Fig. S5). A similar Spearman correlation test was set up using RNA-Seq data of 471 skin cutaneous melanomas described in the TCGA database. A positive correlation was found between the expression of CCL5 and NCR1. The expression of each gene was reported as RNA-Seq V2RSEM (RNA-Seq expression estimation by expectation-maximization) (P1 to P5) are reported. (Scale bars, 100 μm.) (B) RNA extracted from 22 melanoma biopsies were assessed for the expression of CCL5 and NKp46 encoding NCR1 gene. The Spearman test showed a significant and positive correlation between the expression of CCL5 and NCR1. (C) A similar Spearman correlation test was set up using RNA-Seq data of 471 skin cutaneous melanomas described in the TCGA database. A positive correlation was found between the expression of CCL5 and NCR1. The expression of each gene was reported as RNA-Seq V2RSEM (RNA-Seq expression estimation by expectation-maximization).

A Kaplan–Meier survival plot of skin cutaneous melanoma (SKCM) patients generated using Oncomine resource. TCGA data of 458 melanoma patients were assigned into low or high groups according to the expression level of CCL5 reported as RNA-Seq values. Patients having a CCL5 expression level ranging from 7.92 to 588 were considered as low (blue curve) and those having a CCL5 expression level ranging from 32,675 to 32,675 were considered as high (red curve). Statistically significant difference is indicated by P value.
regulated in BECN1+ tumor cells. A schematic representation of the mechanism underlying the expression of CCL5 in BECN1+ cells is reported in Fig. 6. In addition, we strongly believe that the increased-phosphorylation of c-Jun at Ser-63 residue is a consequence of targeting Beclin1 rather than the up-regulation of CCL5, as the level of phosphorylated c-Jun was not affected following CCL5 silencing in BECN1+ tumor cells (Fig. S7).

It is now well established that tumor infiltration by NK cells represents a positive prognostic marker in different cancers, including colorectal (7), gastric (52), and lung carcinomas (53). It has been suggested that low NK cell numbers in tumors are likely to fully exploit NK cells that the knowledge generated from this study will pave the way to fully exploit NK cells’ antitumor properties in clinical settings.

Materials and Methods

Immunoblot Assays. Cell lysates were prepared using RIPA lysis buffer (20-188; Millipore) supplemented with a protease inhibitor mixture (1187358001; Prophac) and phosphatase inhibitor mixture 2 and 3 (PS726-SM and P0044-SM; Sigma). Protein concentration was determined using Bio-Rad protein assay dye reagent (500-0006; Bio-Rad). Equal amounts of proteins were loaded on SDS-PAGE gel, transferred to nitrocellulose membranes, and blocked with either 5% of milk or 5% of BSA according to the manufacturer’s instructions for each antibody. The following primary antibodies were used: Beclin1 (3738; Cell Signaling), c-Jun (9165S; Cell Signaling), phospho c-Jun 583 (9261S; Cell Signaling), phospho c-Jun 573 (3270S; Cell Signaling), LC3II (2775S; Cell Signaling), ATG5 (M8513; MBL), GAPDH (5174S; Cell Signaling), SAPK/JNK (9552S; Cell Signaling), phospho JNK (Thr183/Tyr185) (9251S; Cell Signaling), PP2A subunit A (2041; Cell Signaling), phospho PP2A tyr307 (sc-271903; Santa Cruz), SEK1/MMK4 (9152S; Cell Signaling), phospho SEK1/MMK4 5257 (4514P; Cell Signaling), phospho SEK1/MMK4 580 (9155S; Cell Signaling), phospho SEK1/MMK4 Thr261 (9151S; Cell Signaling), and actin (A5441; Sigma Aldrich). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson Immunoresearch Laboratories). Proteins were detected using enhanced chemiluminescence ECL (GE Healthcare).

RNA Extraction and Reverse-Transcriptase PCR. Total RNAs were extracted using the miRCURY RNA isolation kit (300110; Exiqon). RNA (1 μg) from each sample was reverse-transcribed using a reverse-transcription reaction mix (Eurogentec). The transcription reaction was performed at 48 °C for 30 min. The resulting cDNA was subjected to amplification by qPCR using power SYBR green PCR master mix (Life Technologies). The RPL13 gene encoding Ribosomal Protein L13 was used as internal control. For mouse RPL13, the following primers were used: forward 5′-GGAGGGCGGAGGTCTTGAT-3′ and reverse 5′-GGAGGGCGGAGGTCTTGAT-3′. For mouse CCL5, the following primers were used: forward 5′-CGTGTGGTGTGGCCTGGT-3′ and reverse 5′-GGAGGGCGGAGGTCTTGAT-3′. For human CCL5, the following primers were used: forward 5′-TCTGGTGGTGGCCTGGT-3′ and reverse 5′-GGAGGGCGGAGGTCTTGAT-3′. For human CCL5, RNAs from melanoma patients were provided by the Gustave Roussy Cancer Center, Villejuif, France. Briefly, RNAs from frozen melanoma were extracted using the Qiagen miRNKasy extract kit (217004; Courta-boveil) and those from formalin-fixed paraffin-embedded (FFPE) were extracted using the Qiagen RNasy FFPE kit (73504; Qiagen). RNAs were quantified by Nanodrop and their quality was verified by Bioanalyzer. The reverse-transcription qPCR was performed by AnyGenes Company (Tenon Hospital, Paris). Information related to the primers used is available upon request. The results were analyzed using the following: pPIA and ACTB genes encoding Peptidylprolyl isomerase A and actin, respectively, were used as internal loading controls; for Nkp46 encoding NCR1 gene, the forward primer is localized in exon 4 and the reverse primer is localized at the junction of exons 4 and 5; for CCL5, the forward and reverse primers are localized in exon 1 and 2, respectively; for PPA, the forward and reverse primers are localized in exon 1 and 2, respectively; and for ACTB, the forward and reverse primers are localized in exon 6.

Cytokine Array and ELISA Measurement of Mouse and Human CCL5. The profiling of cytokines and chemokines was performed by Mouse cytokine array, and panel A (R&D systems) according to the manufacturer’s instructions using serum-free supernatant harvested from equal number of cells. The signal intensities of the spots were measured using ImageJ. CCL5 secretion by cells was quantified using the CCL5/RANTES Quantikine ELISA kit (R&D Systems) according to the manufacturer’s instructions. The sensitivity of ELISA kits was 2.0 pg/ml for mouse CCL5 and 5.0 pg/ml for human CCL5.

In Vivo Tumor Growth and Flow Cytometry Analysis. Nine-week-old C57BL6 mice were engrafted subcutaneously with B16F10 melanoma cells (2.3 × 10^6).
cells per mouse). Tumor growth was measured using a caliper every other day starting from day 11. Tumor volume was calculated as follows: volume (cm$^3$) = $\frac{\text{width} \times \text{length} \times \text{height}}{2}$. B16-F10 tumor-bearing C57BL/6 mice were killed at day 21. The mouse experiments were performed according to the Luxembourg Institute of Health's instructions and guidelines and approved by the Luxembourg Institute of Health Ethical Committee. For flow cytometry analysis, cells were dissociated from tumors in DMEM complete medium, and centrifuged for 10 min at 4 °C. Red blood cells were lysed using ACK lysis buffer (10-548E; Lonza). Cells were counted and Fc-receptors were blocked with CD16/CD32 for 30 min before staining with appropriate antibodies. The following antibodies were used: BV421 anti-mouse for 11.1 (108731; Biolegend), A1700 anti-mouse CD19 (115528; Biolegend), APC-R700 rat anti-mouse CD11b (564987; BD Horizon), BVU395 rat anti-mouse CD45 (564279; BD Horizon), BV605 Hamster anti-mouse CD69 (563290; BD Horizon), Pacific blue anti-human/mouse GzmB (5155407; Biolegend) and live/dead near IR (LI0119; Life Technologies). CD45+/CD11b+/CD19+ cells were gated to determine the percentage of NK.1.1, NK.1.1 GzmB+ and NK.1.1 CD69+.

**Immunohistochemistry Staining.** FFPE tumor sections (5 μm) from B16-F10 tumors were used to determine the expression of NK and CCL5/RANTES by immunohistochemistry using rabbit anti-Axial GM1 glycolipid antibody (986-10001; Wako Chemicals) and CCL5/RANTES antibody (NBIP-19769; Novus Biologicals) respectively. The staining was performed at the Laboratory of Experimental Pathology, Gustave Roussy Cancer Center, Villejuif, France. Stained sections were washed with the Leica Aperio AT2 scanner and the number of NK+ and CCL5+ cells were quantified by HistoWiz Company using HALO software from Indica laboratories. FFPE sections from melanoma patients were assessed for the expression of CCL5 and Nkp46 using NBIP-19769 and NBP2-11820 antibodies (Novus Biologicals), respectively. Stained sections were scanned with the Leica Aperio AT2 and HistoWiz.

**Cell Culture and Treatments.** B16-F10 cells from ATCC were maintained in DMEM supplemented with 10% of FBS and 1% of penicillin/streptomycin. IPC298, MelUso and A375 cells were provided by S.K. and were maintained in RPMI medium supplemented with 10% of FBS and 1% of penicillin/streptomycin. B16-F10 cells were treated with 60 μM of chloroquine during 4 h or with 20 μM of SP600125 overnight and washed before harvesting RNAs and proteins.

**PP2A In Vitro Protein Phosphatase Assay.** A PP2A immunoprecipitation phosphate assay kit (Millipore) was used to detect PP2A activity according to the manufacturer’s instructions. Briefly, 200 μg of Ctrl and BECN1- B16-F10 cells lysates were used to immunoprecipitate PP2A using anti-PP2Ac antibody. PP2A bound beads were washed with phosphate assay buffer (KRpTIRR) in serine/threonine assay buffer (750 μM). F10 cells lysates were used to immunoprecipitate PP2A using anti-PP2Ac antibody. PP2A bound beads were washed with phosphatase assay buffer (KRpTIRR). CCL5/RANTES expression in Mφs was assessed by Flow cytometry using APC-R700 rat anti-mouse CD11b (564985; BD Horizon) and Fc receptors were blocked with CD16/CD32 for 30 min before staining. The following antibodies were used: SI0005594 for IPC298 and A375, SI00055573 for MelJuso. siRNA against mouse JNK1 was SI01300691. siRNA against JNK2 was SI01300691. Transfected cells were harvested for RNA and protein extractions.

**In Vivo Chemotaxis Experiment.** The migration of NK92MI cells was evaluated in a Slide Chemotaxis® from ibidi according to the manufacturer’s instructions. NK92MI cells (9 × 10^6 cells/mL) cultured in serum-free medium in the absence or presence of 20 ng/mL of human recombinant CCL5/RANTES were transferred to the ibidi slide reservoirs. The time-lapse experiment was performed using Cell IQ platform during 48 h. One image was recorded every 15 min and the migration of NK92MI cells was analyzed by Tracking Tool PRO v2.0 software.

**siRNA Transfections.** Small interference RNAs (siRNA) were purchased from Qiagen. Cells were transfected using Lipofectamine RNAiMax reagent (13778-075; Life Technologies) in Opti-MEM reduced serum medium (31985070; Thermo Fisher Scientific). The following siRNAs against human Beclin1 were used: SIO005594 for IPC298 and A375, SI00055573 for MelUso. siRNA against mouse ATG5 was SI0268800. siRNA against mouse p62 was SI02713445 (Qiagen). siRNAs against mouse JNK1 was SI01300691. siRNA against JNK2 was SI01300691. Transfected cells were harvested for RNA and protein extractions.

**In Vivo Experiments and Clinical Samples.** In vivo protocols were approved by the “Comité National d’Ethique de Recherche” Luxembourg. LHCE-2014-02. Clinical samples were collected from patients after having given their written informed consent in accordance with the declaration of Helsinki.

**Statistical Analysis.** Statistically significant differences were evaluated using the unpaired two-tailed t-test (SigmaPlot 12.5). A p value of less than 0.05 was considered statistically significant. Data were expressed as average ± SEM. The Spearman test was used to determine the correlation between the expression of CCL5 and Nkp46 encoding NCR1 genes in melanoma patients. Melanoma patients’ survival curves were generated by the OncoLnc tool (open access), which uses the Kaplan–Meier method for generating the curves and a log-rank test for calculating P values.

**ACKNOWLEDGMENTS.** We thank Lea Guyonnet from the National Cytochemistry Platform at Luxembourg Institute of Health for her assistance in flow cytometry analysis; Olivia Bawwa from the Gustave Roussy Cancer Center for her assistance in immunohistochemistry staining; and Cristina Maximo from Luxembourg Institute of Health for proofreading the manuscript. This work was supported by grants from Fond National de la Recherche, Luxembourg (Grant FNR-APR 7842786 to T.M.), Luxembourg Institute of Health (Grant LHCE 2013 11.05 to B.J.), Fondés de la Recherche Scientifique FNRS Televie (Grants 7.6503.16 to T.A. and B.J., 7.4664.15 to M.Z.N. and B.J., and 7.4571.15 to E.V. and B.J.), Fondation Cancer, Luxembourg (Grants FC/2012/02 and F/2016/01 to B.J. and G.B.), Calouste Gulbenkian Foundation (Grant P.1333273 to T.M. and B.J.), Ligue Contre le Cancer (Equipes Labellisées), and Institut National du Cancer (to C.).

8. Meleo L, Rouzaud A, Mott CT, Coulon G (2014) Tcell and NK cell infiltration into solid tu-


